Pharmaceutical Companies

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.

Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.

The project is supported by the Ministry of Health and Social Protection together with the National Health Institute (Instituto Nacional de Salud), which will coordinate regulatory oversight and public health integration.

The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.

Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.

If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.

The product will be manufactured and commercialized to support treatment and prevention needs during influenza seasons, with an emphasis on improving availability for younger patients across China.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.